Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cisco Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225 (market cap $29.97B), while Cisco Systems Inc trades at $115.35 (market cap $488.26B). The key difference: Cisco Systems Inc is far larger — about 16.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Cisco Systems Inc pays a 1.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CSCO | |
|---|---|---|
Market Cap | $29.97B | $488.26B |
Sector | Health | Technology |
52-Week High | $491.22 | $130.00 |
52-Week Low | $205.48 | $66.20 |
Enterprise Value | $27.93B | $501.88B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Cisco Systems (CSCO) trades at $120.43, down 1.75% on the day, but maintains strong technical momentum with a bullish moving average signal. The company has delivered four consecutive quarterly earnings beats, with Q2 2026 EPS of $1.22 exceeding expectations. Recent AI cybersecurity partnerships and product launches have driven positive sentiment, though valuation metrics remain elevated with a P/E of 40.14.
The outlook remains positive with analyst consensus pointing to 11% upside to the $133.60 price target. Key opportunities include Cisco's strategic positioning in AI infrastructure and cybersecurity, while risks include competitive pressures and the stock's premium valuation. Institutional ownership remains strong with 52% of analysts maintaining buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
